Trials / Completed
CompletedNCT06170619
Obsidio™ Conformable Embolic Registry
A Prospective, Post-Approval, Open-Label, Multi-Center United States (US) Registry to Evaluate the Effectiveness and Safety of Obsidio in Clinical Practice
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 125 (actual)
- Sponsor
- Boston Scientific Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
OCCLUDE is a prospective, post-approval, open-label, single arm, multi-center US registry of patients who undergo embolization with Obsidio™ Conformable Embolic. The purpose of this Registry is to assess effectiveness and safety outcomes of subjects who undergo embolization with Obsidio.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Obsidio™ Conformable Embolic | Embolization with Obsidio™ Conformable Embolic. |
Timeline
- Start date
- 2024-06-19
- Primary completion
- 2025-09-09
- Completion
- 2025-09-09
- First posted
- 2023-12-14
- Last updated
- 2026-03-17
Locations
20 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT06170619. Inclusion in this directory is not an endorsement.